comprehensive -WSS

comprehensive

author：knowledge 2025-08-26 03:41:39 - browse：75331

Becton Dickinson plans to pay $4.2 billion for Edwards Lifesciences’ critical care business, which sells technology that monitors the heart conditions of critically ill patients.

Edwards had told investors in December 2023 that it planned to spin off the business in order to focus more sharply on addressing structural defects in the heart. BD, meanwhile, wants to increase its monitoring presence in hospitals. In a statement announcing the acquisition, the company touted the “advanced AI algorithms” used in Edwards’ monitors.

BD CEO Tom Polen said in a statement that the acquisition will bolster BD’s portfolio of “AI-enabled clinical decision tools” and digital health products in general.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Investigation reveals sickle cell patients pressured into sterilizations

leisure time

focus

WSS

H5N1 bird flu outbreak: Second human case reported, in Michigan

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

FDA early review: GLP

Allen Institute goes after foundational questions, CEO Costa says

Hospital chaplains balance Covid safety with patients’ spiritual needs

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Virginia high school admissions case could be legal follow

Male doctors called my cancer incurable. A female doctor showed it wasn't

Cancer drug shortages should be causing more outrage

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Hollywood unions extend contract negotiations for actors

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Alkermes shareholders re

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

In Memoriam: Notable people who died in 2023

Reports of telehealth's death have been greatly exaggerated

focus

UnitedHealth argues against case alleging wrongful AI care denials

Scrutiny of post

Study finds gene variants tied to breast cancer risk in Black women

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Allen Institute goes after foundational questions, CEO Costa says

At flashy new research hub, AstraZeneca lays out ambitious growth goals

knowledge

leisure time

focus

knowledge